title: Darbepoetin alfa administration in patients with non-Hodgkin lymphoma and chemotherapy-induced anemia receiving (±R) CHOP.
abstract: IMPACT NHL was a multicenter, observational study in adults with non-Hodgkin lymphoma receiving CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) chemotherapy with or without rituximab. Erythropoietin-stimulating agent treatment was given according to routine clinical  practice and physician preference. In a subanalysis, outcomes were evaluated in 207 patients who received darbepoetin alfa (DA). The most common reason (81%) for initiating DA was low/declining hemoglobin (Hb) concentration. Mean (±standard deviation) duration of DA exposure was 8.8 ± 6.9  weeks (mean number of doses, 5.1 ± 4.6). Overall, 23% of patients had chemotherapy and DA treatment synchronized more than 75% of the time. At the time of DA initiation, 67% of patients had Hb concentrations in the guideline-recommended range (9-11 g/dl). Of 89  patients with Hb concentrations <10 g/dl at DA initiation and still receiving DA 5 weeks later, 92% (Kaplan-Meier) achieved Hb concentrations 10-12 g/dl between week 5 and at the end of treatment.
authors.affiliation: Haematology, St George's University of London, London SW17 0RE, UK. rpetteng@sgul.ac.uk
authors.forename: Ruth
authors.initials: R
authors.lastname: Pettengell
authors.forename: Antonio Salar
authors.initials: AS
authors.lastname: Silvestre
authors.forename: Matthias
authors.initials: M
authors.lastname: Schwenkglenks
authors.forename: Francesca Gaia
authors.initials: FG
authors.lastname: Rossi
authors.forename: Ulrich
authors.initials: U
authors.lastname: Duehrsen
authors.forename: Gregor
authors.initials: G
authors.lastname: Verhoef
authors.forename: Pieternella Johanna
authors.initials: PJ
authors.lastname: Lugtenburg
authors.forename: Tracey
authors.initials: T
authors.lastname: Wheeler
authors.forename: Beatriz
authors.initials: B
authors.lastname: Pujol
authors.forename: Corinne
authors.initials: C
authors.lastname: Haioun
mesh_terms: D000740:Anemia / Q000139:chemically induced* / Q000188:drug therapy*; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D000068256:Darbepoetin alfa; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D004334:Drug Administration Schedule; D004921:Erythropoietin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006397:Hematinics / Q000627:therapeutic use*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000097:blood* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage / Q000009:adverse effects; D000069283:Rituximab; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D006397:Hematinics; D004921:Erythropoietin; D000068256:Darbepoetin alfa; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone